2026-08-20 · Notice · 2026-16998
Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal
Exenatide
Open attributed record →Federal Register publication year
2026 FDA Federal Register peptide records
10 documents attributed to FDA and HHS and published in 2026, connected only through exact reviewed peptide-name matches.
2026-07-29 · Notice · 2026-15285
Product-Specific Guidances; Revised Draft Guidances for Industry; Availability
Glucagon + Liraglutide + Semaglutide + Teriparatide + Tirzepatide + Vosoritide
Open attributed record →2026-06-26 · Notice · 2026-12937
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
Liraglutide + Semaglutide + Tirzepatide
Open attributed record →2026-05-01 · Notice · 2026-08552
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Glucagon + Liraglutide + Semaglutide + Tirzepatide
Open attributed record →2026-04-30 · Notice · 2026-08435
Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Semaglutide
Open attributed record →2026-04-22 · Rule · 2026-07863
Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Setmelanotide Eligibility Gene Variant Detection System
Setmelanotide
Open attributed record →2026-04-16 · Notice · 2026-07361
Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
BPC-157 + Emideltide + Epitalon + KPV + MOTS-c + Semax + TB-500
Open attributed record →2026-03-09 · Notice · 2026-04546
Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
Exenatide
Open attributed record →2026-02-27 · Notice · 2026-03963
Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
Octreotide + Semaglutide
Open attributed record →2026-02-12 · Notice · 2026-02786
Jeremy Spencer Brown: Final Debarment Order
Semaglutide
Open attributed record →